αs saa  (Amprion Inc)

Journal: bioRxiv

Article Title: Borrelia Burgdorferi binds Serum Amyloid A and Modulates Subcutaneous Adipose Tissue Immune Signaling

doi: 10.64898/2026.01.29.702514

Figure Lengend Snippet: Single Cell RNA Sequencing (scRNA seq) (10X Genomics) of 31,953 adipose tissue stromal vascular fraction (SVF) cells (13,023 from Bb-infected tissue, 18,930 from uninfected tissue) (n=3 Uninfected control, n=2 Bb- infected tissue specimens). (A) Uniform Manifold Approximation and Projection (UMAP) plots indicate 7 unique cell types with a total of 10 clusters. (B) Bubble plot shows adipose stem/progenitor cells and monocyte/macrophage (Mono/Mø) clusters and their expressed immune focused pathways from MSigDB Hallmark gene sets. (C) Total SAA (SAA1+SAA2) gene expression across tissue cohorts. (D) SAA-related genes expressed per cluster showing average expression across cell type and percent of cells expressing each gene of interest. Genes upregulated during infection were plotted in red and genes downregulated after infection plotted in blue. The size of the bubble is based on the percentage of cells within that cell type cluster expression each gene. (E) Total SAA gene expression (SAA1+SAA2) across cell clusters within each tissue cohort. Abbreviations: ASPC: adipose stem/progenitor cells; LEC: lymphatic endothelial cells; Mono/Mø: monocytes/macrophages; SMC: smooth muscle cells.

Article Snippet: Spirochetes were pelleted at 5000 x g for 5 minutes, washed with 1x PBS, then resuspended in solution with SAA2 recombinant protein (hSAA2-His: MedChemExpress HY-P70985, Elabscience PKSH033532; mSAA2-His: antibodies online ABIN7088660) at 1μg/mL, 10μg/mL or 40μg/mL for 1h at room temperature.

Techniques: Single Cell, RNA Sequencing, Infection, Control, Gene Expression, Expressing

Journal: bioRxiv

Article Title: Borrelia Burgdorferi binds Serum Amyloid A and Modulates Subcutaneous Adipose Tissue Immune Signaling

doi: 10.64898/2026.01.29.702514

Figure Lengend Snippet: SAA2-bound spirochetes were stained for the presence of attached His-tagged protein (SAA2) detected by flow cytometry using an anti-His-tag fluorescent (PE/Cy5) conjugated antibody. (A) Histogram plots showing human SAA (hSAA2 and hSAA1), relative to non-stained controls (grey) and positive control protein (brown) known to bind Borrelia (Peptidoglycan Recognition Protein 1 (PGLYRP1) – Ref 39). The dashed line represents 40 µg/mL of hSAA2. The solid line represents 10µg/mL hSAA2. (B) Streptococcus pneumoniae incubated with 40µg/mL recombinant hSAA2 showing no increase in fluorescence compared to control. (C) Repeat binding assays showing histograms representing SAA2 binding multiple isolates of Bb sensu stricto (B31, CA8, HP19, CT-1, NT-1).

Article Snippet: Spirochetes were pelleted at 5000 x g for 5 minutes, washed with 1x PBS, then resuspended in solution with SAA2 recombinant protein (hSAA2-His: MedChemExpress HY-P70985, Elabscience PKSH033532; mSAA2-His: antibodies online ABIN7088660) at 1μg/mL, 10μg/mL or 40μg/mL for 1h at room temperature.

Techniques: Staining, Flow Cytometry, Positive Control, Incubation, Recombinant, Fluorescence, Control, Binding Assay

Journal: bioRxiv

Article Title: Borrelia Burgdorferi binds Serum Amyloid A and Modulates Subcutaneous Adipose Tissue Immune Signaling

doi: 10.64898/2026.01.29.702514

Figure Lengend Snippet: (A) Experimental workflow diagram of flow cytometry binding assay. Spirochetes cultured at 37°C for 24h were allowed to bind recombinant His-tagged mSAA2. Anti-His tag fluorescent (PE/Cy5) primary conjugated antibodies were bound to SAA-spirochete complexes to label protein attached to spirochetes. Spirochetes were washed and used for flow cytometry analysis compared to unstained spirochete complexes. (B) Histogram plots indicating murine SAA2 (mSAA2) binds SAA2 relative to staining control ( Bb + mSAA2) and positive control protein peptidoglycan recognition protein-1 (PGLYRP1 ref 39). (C) Binding of mSAA2 to Bb sensu stricto strains B31, CA8, HP19, CT-1, NT-1.

Article Snippet: Spirochetes were pelleted at 5000 x g for 5 minutes, washed with 1x PBS, then resuspended in solution with SAA2 recombinant protein (hSAA2-His: MedChemExpress HY-P70985, Elabscience PKSH033532; mSAA2-His: antibodies online ABIN7088660) at 1μg/mL, 10μg/mL or 40μg/mL for 1h at room temperature.

Techniques: Flow Cytometry, Binding Assay, Cell Culture, Recombinant, Staining, Control, Positive Control

Journal: bioRxiv

Article Title: Borrelia Burgdorferi binds Serum Amyloid A and Modulates Subcutaneous Adipose Tissue Immune Signaling

doi: 10.64898/2026.01.29.702514

Figure Lengend Snippet: (A) Workflow diagram of labeled spirochetes added to stained cells to be measured by flowcytometry. Spirochetes were allowed to bind SAA2 previously described and labeled with CFSE. Separately, differentiated THP-1 macrophage-like cells were labeled with membrane stain DiD. Labeled spirochetes were added to stained cells and harvested at 0.5-3.0h post incubation at 37°C. (B) Flow cytometry controls of CFSE-stained Bb N40 spirochetes (green) and DiD-labeled cells (red) showing detection capability of both positive- and negative-stained populations. (C) Contour plots of THP-1 cells and spirochetes incubated with either hSAA2, 5% normal human serum (NHS), and hPGLYRP1 (10µg) comparing levels of double positive populations over time (0.5, 1.0, 2.0, 3.0h in co-culture). Contour plots show percentages of cells in each quadrant in which triplicate plots overlayed. Each replicate value from quadrant 2 (top right) used for quantification .

Article Snippet: Spirochetes were pelleted at 5000 x g for 5 minutes, washed with 1x PBS, then resuspended in solution with SAA2 recombinant protein (hSAA2-His: MedChemExpress HY-P70985, Elabscience PKSH033532; mSAA2-His: antibodies online ABIN7088660) at 1μg/mL, 10μg/mL or 40μg/mL for 1h at room temperature.

Techniques: Labeling, Staining, Membrane, Incubation, Flow Cytometry, Co-Culture Assay

Journal: NPJ Precision Oncology

Article Title: Comprehensive single-cell RNA analysis reveals intertumoral microenvironment heterogeneity and hub niche of carcinogenesis in thyroid cancer

doi: 10.1038/s41698-025-00924-7

Figure Lengend Snippet: A Circle plot summarizing the maximum number of interactions among individual cell types in metastatic lesions. The thickness of the connecting lines represents the interaction strength. B Comparison of the overall information flow, including the number and strength of interactions, within the inferred networks between PTC and metastatic lesions. C Heatmap displaying the potential outgoing and incoming interaction strength of each cellular cluster in PTC and metastatic lesions. D Heatmap illustrating the relative signaling contribution of each cell group based on the number and strength of interactions, comparing PTC with metastatic lesions. E Differential network centrality analysis based on EMT-like cancer-associated fibroblasts (CAFs), comparing PTC and metastatic lesions. F Bubble heatmap showing the cell-cell communication of selected ligand-receptor pairs between EMT-like CAFs and CD8 + PDCD1 + T cells. Dot size indicates the P -value, while color represents the communication probability. G Multiplex immunohistochemistry (mIHC) validation of the cross-talk between SAA1+ CAFs and T cells via the PPIA-BSG ligand-receptor interaction.

Article Snippet: We performed multiplex immunofluorescence staining using the following primary antibodies: THBS1 rabbit anti-human antibody (Affinity Biosciences; catalog no. DF6848), CD47 rabbit anti-human antibody (Affinity Biosciences; catalog no. DF6649), CD68 rabbit anti-human antibody (Affinity Biosciences; catalog no. DF7518), APOE rabbit anti-human antibody (Affinity Biosciences; catalog no. AF5178), CD3 rabbit anti-human antibody (Affinity Biosciences; catalog no. DF6848), THBS1 rabbit anti-human antibody (Affinity Biosciences; catalog no. DF6594), BSG rabbit anti-human antibody (Affinity Biosciences; catalog no. AF5221), COL3A1 rabbit anti-human antibody (Affinity Biosciences; catalog no. AF5457), PPIA rabbit anti-human antibody (Proteintech Group; catalog no. 10720-1-AP), and SAA1 rabbit anti-human antibody (Proteintech Group; catalog no. 16721-1-AP).

Techniques: Comparison, Multiplex Assay, Immunohistochemistry, Biomarker Discovery

Journal: Movement Disorders Clinical Practice

Article Title: Evaluating the Role of α‐Synuclein Seed Amplification as a Disease Progression Marker: Evidence and Uncertainties

doi: 10.1002/mdc3.70434

Figure Lengend Snippet: Flow chart showing selection of individuals. This includes individuals who had both versions of the αS‐SAA. α‐synuclein seeding aggregation assay (αS‐SAA), neurofilament light chain (NfL).

Article Snippet: Fmax in the Amprion‐150 h αS‐SAA improved model fit for HVLT‐R delayed recall ( P = 0.02) and RDI (0.04), and GDS (0.03).

Techniques: Selection

Journal: Movement Disorders Clinical Practice

Article Title: Evaluating the Role of α‐Synuclein Seed Amplification as a Disease Progression Marker: Evidence and Uncertainties

doi: 10.1002/mdc3.70434

Figure Lengend Snippet: Change in kinetic parameters between the Amprion‐24 h αS‐SAA and Amprion‐150 h αS‐SAA version in the same individual's baseline CSF.

Article Snippet: Fmax in the Amprion‐150 h αS‐SAA improved model fit for HVLT‐R delayed recall ( P = 0.02) and RDI (0.04), and GDS (0.03).

Techniques:

Journal: Movement Disorders Clinical Practice

Article Title: Evaluating the Role of α‐Synuclein Seed Amplification as a Disease Progression Marker: Evidence and Uncertainties

doi: 10.1002/mdc3.70434

Figure Lengend Snippet: Flow chart showing selection of individuals. This includes individuals who had both versions of the αS‐SAA. α‐synuclein seeding aggregation assay (αS‐SAA), neurofilament light chain (NfL).

Article Snippet: Analysis of kinetic parameters in the secondary outcomes found model fit for RBDSQ question‐6 was improved when TTT ( P = 1.63e−04), T50 ( P = 4.59e−04) and AUC ( P = 1.81e−03) from the Amprion‐150 h αS‐SAA version were added to the basic model(Table ).

Techniques: Selection

Journal: Movement Disorders Clinical Practice

Article Title: Evaluating the Role of α‐Synuclein Seed Amplification as a Disease Progression Marker: Evidence and Uncertainties

doi: 10.1002/mdc3.70434

Figure Lengend Snippet: Change in kinetic parameters between the Amprion‐24 h αS‐SAA and Amprion‐150 h αS‐SAA version in the same individual's baseline CSF.

Article Snippet: Analysis of kinetic parameters in the secondary outcomes found model fit for RBDSQ question‐6 was improved when TTT ( P = 1.63e−04), T50 ( P = 4.59e−04) and AUC ( P = 1.81e−03) from the Amprion‐150 h αS‐SAA version were added to the basic model(Table ).

Techniques: